We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 03, 2021

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
J. Clin. Oncol 2021 Apr 23;[EPub Ahead of Print], KN Moore, M Bookman, J Sehouli, A Miller, C Anderson, G Scambia, T Myers, C Taskiran, K Robison, J Mäenpää, L Willmott, N Colombo, J Thomes-Pepin, M Liontos, MA Gold, Y Garcia, SK Sharma, CJ Darus, C Aghajanian, A Okamoto, X Wu, R Safin, F Wu, L Molinero, V Maiya, VK Khor, YG Lin, S Pignata

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading